
CJC-1295 dosage in published studies
Research amounts belong to a particular study. There is no FDA-labeled dose for CJC-1295.
An amount is only part of a study
A dosage question needs more than a number. It needs an identified ingredient, a route of administration, a participant group, an observation period, and a reason for measuring an outcome. Without those details, a quantity taken from a paper loses much of its meaning.
CJC-1295 has no FDA-approved product or prescribing label. Its early studies tested pharmacology: how long the compound remained in the body and how growth hormone and IGF-1 responded. They did not establish an effective treatment regimen for sleep, muscle gain, fat loss, or recovery.
The amounts described below are historical study facts. They are not instructions for use, a starting point, or a range to adjust. A study can identify a biological response at a given exposure without establishing a suitable dose for any medical condition. The human research overview explains that difference in more detail.
Which CJC-1295 was studied
The published human findings concern the DAC form. DAC means Drug Affinity Complex, the chemical addition that lets the peptide attach to albumin in blood. That attachment contributes to the prolonged exposure documented in healthy volunteers.
FDA's evaluation treats CJC-1295 with and without DAC as different active ingredients. It found no human studies of the form without DAC. A no-DAC name therefore cannot inherit the dose-response findings, half-life, or safety experience of the long-acting form.
The addition of ipamorelin is a further change. Ipamorelin acts through the ghrelin receptor, a different part of the growth hormone signaling system. A rationale for combining two pathways does not establish the amounts, timing, or safety of a fixed blend. The reviewed record contains no controlled human trial of that combination.
What the studies used
In the 2006 study by Teichman and colleagues, researchers administered single subcutaneous CJC-1295 doses of 30 or 60 micrograms per kilogram in healthy adults and reported prolonged hormone changes. The published study describes single- and multiple-dose investigations, with drug persistence and hormone measurements as central outcomes.
These weight-based amounts are reported to describe the experiment. Converting them into a personal amount would leave unanswered the clinical purpose, the exact formulation, the person's health, and whether the exposure has a favorable balance of benefits and harms. This page provides no conversion or schedule.
For a combination product, single-ingredient data are particularly easy to misread. A prescription decision about a blend is a separate question from what a trial administered as CJC-1295 alone.
Why half-life does not set a schedule
Teichman's study estimated a CJC-1295 half-life of 5.8–8.1 days in healthy adults. The half-life estimate describes a halving of the amount in circulation over a measured period. It is a description of persistence, not an endorsed interval between administrations.
Drug concentration, growth hormone, and IGF-1 also describe different measurements. Their peaks and return toward baseline need not happen together. A longer effect does not establish that repeated exposure is safe, nor does it show that a more frequent or less frequent schedule would be useful.
The short duration of published follow-up remains a limit even when hormone measurements are precise. Long-term adverse effects, effectiveness for a condition, and interactions with other treatment require their own evidence. None can be derived from the half-life alone.
Questions for a prescriber
A useful discussion begins with the intended health problem, rather than a requested peptide amount. Which diagnosis is being considered? What approved options exist? Which exact ingredient is proposed, and what evidence concerns that form and that condition? What uncertainties remain if a blend is involved?
Regulatory status belongs in the same discussion. FDA's safety-risk page, current as of April 22, 2026, places CJC-1295 among nominations that were withdrawn. That status is not permission to compound, a new approval, or evidence that safety concerns were resolved. FDA publishes no date for this individual withdrawal.
This guide cannot select treatment or assess eligibility. It can help keep a research quantity attached to its source and prevent a study finding from becoming an unsupported personal regimen. The effects page covers adverse reactions and the limits of current safety knowledge.